PKM2 promotes glioma progression by mediating CTNNB1 expression

References

• Moncayo G, Grzmil M, Smirnova T, et al. SYK inhibition blocks proliferation and migration of glioma cells and modifies the tumor microenvironment. Neuro Oncol. 2018;20(5):621–631. doi: 10.1093/neuonc/noy008
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23(8):1231–1251. doi: 10.1093/neuonc/noab106
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507. doi: 10.1056/NEJMra0708126
   PubMed Web of Science ®Google Scholar
• Lan YL, Zhu Y, Chen G, et al. The promoting effect of traumatic brain injury on the incidence and progression of glioma: a review of clinical and experimental research. J Inflamm Res. 2021;14:3707–3720. doi: 10.2147/JIR.S325678
   PubMed Web of Science ®Google Scholar
• Braganza MZ, Kitahara CM, Berrington de González A, et al. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol. 2012;14(11):1316–1324. doi: 10.1093/neuonc/nos208
   PubMed Web of Science ®Google Scholar
• Lu M, Wang Y, Zhou S, et al. MicroRNA-370 suppresses the progression and proliferation of human astrocytoma and glioblastoma by negatively regulating β-catenin and causing activation of FOXO3a. Exp Ther Med. 2018;15:1093–1098. doi: 10.3892/etm.2017.5494
   PubMed Web of Science ®Google Scholar
• Kranjc MK, Novak M, Pestell RG, et al. Cytokine CCL5 and receptor CCR5 axis in glioblastoma multiforme. Radiol Oncol. 2019;53(4):397–406. doi: 10.2478/raon-2019-0057
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2015–2019. Neuro Oncol. 2022;24(Supplement_5):v1–v95. doi: 10.1093/neuonc/noac202
   PubMedGoogle Scholar
• Dimou J, Beland B, Kelly J. Supramaximal resection: a systematic review of its safety, efficacy and feasibility in glioblastoma. J Clin Neurosci. 2020;72:328–334. doi: 10.1016/j.jocn.2019.12.021
   PubMed Web of Science ®Google Scholar
• Weller M, Wick W, Aldape K, et al. Glioma. Nat Rev Dis Primers. 2015;1(1):15017. doi: 10.1038/nrdp.2015.17
   PubMed Web of Science ®Google Scholar
• Park JH, Lee JS, Oh Y, et al. PKM2 is overexpressed in Glioma Tissues, and its inhibition highly increases late apoptosis in U87MG cells with low-density specificity. Vivo (Athens, Greece). 2022;36(2):694–703. doi: 10.21873/invivo.12755
   PubMed Web of Science ®Google Scholar
• Park JH, Kundu A, Lee SH, et al. Specific pyruvate kinase M2 inhibitor, compound 3K, induces autophagic cell death through disruption of the glycolysis pathway in ovarian cancer Cells. Int J Biol Sci. 2021;17(8):1895–1908. doi: 10.7150/ijbs.59855
   PubMed Web of Science ®Google Scholar
• Zhu H, Luo H, Zhu X, et al. Pyruvate kinase M2 (PKM2) expression correlates with prognosis in solid cancers: a meta-analysis. Oncotarget. 2017;8(1):1628–1640. doi: 10.18632/oncotarget.13703
   PubMedGoogle Scholar
• He S, Tang S. WNT/β-catenin signaling in the development of liver cancers. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2020;132:110851. doi: 10.1016/j.biopha.2020.110851
   PubMed Web of Science ®Google Scholar
• Wen J, Min X, Shen M, et al. ACLY facilitates colon cancer cell metastasis by CTNNB1. J Exper Cli Can Res CR. 2019;38(1):401. doi: 10.1186/s13046-019-1391-9
   PubMed Web of Science ®Google Scholar
• Parrish ML, Broaddus RR, Gladden AB. Mechanisms of mutant β-catenin in endometrial cancer progression. Front Oncol. 2022;12:1009345. doi: 10.3389/fonc.2022.1009345
   PubMed Web of Science ®Google Scholar
• Li B, Wu S, Qiu Z, et al. The predictive value and correlation of β-catenin, CMTM6, and PD-L1 expression in colorectal cancer. Neoplasma. 2022;69(3):691–699. doi: 10.4149/neo_2022_210809N1122
   PubMed Web of Science ®Google Scholar
• Li H, Li T, Huang D, et al. Long noncoding RNA SNHG17 induced by YY1 facilitates the glioma progression through targeting miR-506-3p/CTNNB1 axis to activate Wnt/β-catenin signaling pathway. Cancer Cell Int. 2020;20(1):29. doi: 10.1186/s12935-019-1088-3
   PubMed Web of Science ®Google Scholar
• Chen J, Zhou Q, Feng J, et al. Activation of AMPK promotes thyroid cancer cell migration through its interaction with PKM2 and β-catenin. Life Sci. 2019;239:116877. doi: 10.1016/j.lfs.2019.116877
   PubMed Web of Science ®Google Scholar
• Zhao Z, Song Z, Liao Z, et al. PKM2 promotes stemness of breast cancer cell by through Wnt/β-catenin pathway. Tumour Biol. 2016;37(3):4223–4234. doi: 10.1007/s13277-015-4121-8
   PubMedGoogle Scholar
• Pang F, He W, Liu X, et al. Overexpression of PRKCH promotes tumorigenesis in patients with glioma and influences glioma stem cell properties. Pathol Res Pract. 2022;240:154236. doi: 10.1016/j.prp.2022.154236
   PubMed Web of Science ®Google Scholar
• Ohba S, Tang Y, Johannessen TA, et al. PKM2 interacts with the Cdk1-CyclinB Complex to facilitate cell cycle progression in gliomas. Front Oncol. 2022;12:844861. doi: 10.3389/fonc.2022.844861
   PubMed Web of Science ®Google Scholar
• Verma H, Cholia RP, Kaur S, et al. A short review on cross-link between pyruvate kinase (PKM2) and Glioblastoma Multiforme. Metab Brain Dis. 2021;36(5):751–765. doi: 10.1007/s11011-021-00690-y
   PubMed Web of Science ®Google Scholar
• Gao M, Yang J, Gong H, et al. Trametinib inhibits the growth and aerobic glycolysis of glioma cells by targeting the PKM2/c-Myc Axis. Front Pharmacol. 2021;12:760055. doi: 10.3389/fphar.2021.760055
   PubMed Web of Science ®Google Scholar
• Yang W, Zheng Y, Xia Y, et al. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. Nat Cell Biol. 2012;14(12):1295–1304. doi: 10.1038/ncb2629
   PubMed Web of Science ®Google Scholar
• Wu J, Chen G, Wang W, et al. GTPBP4: a new therapeutic target gene promotes tumor progression in non-small cell lung cancer via EMT. J Oncol. 2022;2022:1–11. doi: 10.1155/2022/2164897
   Web of Science ®Google Scholar
• Li H, Li J, Chen L, et al. HERC3-mediated SMAD7 ubiquitination degradation promotes autophagy-induced EMT and Chemoresistance in Glioblastoma. Clin Cancer Res. 2019;25(12):3602–3616. doi: 10.1158/1078-0432.CCR-18-3791
   PubMed Web of Science ®Google Scholar
• Xiao H, Zhang L, Chen Y, et al. PKM2 promotes breast cancer progression by regulating epithelial mesenchymal transition. Anal Cell Pathol (Amst). 2020;2020:1–10. doi: 10.1155/2020/8396023
   Google Scholar
• Guo W, Zhang Z, Li G, et al. Pyruvate kinase M2 promotes prostate cancer metastasis through regulating ERK1/2-COX-2 signaling. Front Oncol. 2020;10:544288. doi: 10.3389/fonc.2020.544288
   PubMed Web of Science ®Google Scholar
• Zhang J, Cai H, Sun L, et al. LGR5, a novel functional glioma stem cell marker, promotes EMT by activating the Wnt/β-catenin pathway and predicts poor survival of glioma patients. J Exper Cli Can Res CR. 2018;37(1):225. doi: 10.1186/s13046-018-0864-6
   PubMed Web of Science ®Google Scholar
• Basu S, Cheriyamundath S, Ben-Ze’ev A. Cell–cell adhesion: linking Wnt/β-catenin signaling with partial EMT and stemness traits in tumorigenesis. F1000Res. 2018;7:1488. doi: 10.12688/f1000research.15782.1
   Google Scholar